- 1 **RVOT Reconstruction in d-Transposition of the Great Arteries with Ventricular Septal**
- 2 Defect and Pulmonary Obstruction: Male-Female Differences in Clinical and
- 3 **Homograft Function**
- Xu. Wang, MD<sup>1</sup><sup>†</sup>, Isabelle M. Bennink, Bsc<sup>1</sup><sup>†</sup>, Kevin M. Veen, MD, PhD<sup>1</sup>, Pieter C. van de 4
- Woestijne, MD<sup>1</sup>, Carlijn C. E. M. van der Ven, Bsc<sup>1</sup>, Ad J. J. C. Bogers, MD, PhD<sup>1</sup>, Eleni-5
- Rosalina Andrinopoulou, PhD<sup>2,3</sup>, Wim. A. Helbing, MD, PhD<sup>4</sup>, Johanna J.M. Takkenberg, 6
- MD,  $PhD^1$ 7
- <sup>1</sup>Department of Cardiothoracic Surgery, Erasmus University Medical Center Rotterdam, 8
- 9 Rotterdam, The Netherlands.
- <sup>2</sup>Department of Biostatistics, Erasmus University Medical Center Rotterdam, Rotterdam, 10
- 11 The Netherlands.
- <sup>3</sup>Department of Epidemiology, Erasmus University Medical Center Rotterdam, Rotterdam, 12
- The Netherlands. 13
- <sup>4</sup> Department of Pediatric Cardiology, Erasmus University Medical Center Rotterdam, 14
- 15 Rotterdam, The Netherlands.
- 16 <sup>†</sup> These two authors contributed equally to this paper
- Address for correspondence: 17
- \*Corresponding author: Johanna J.M. Takkenberg, MD, PhD. 18
- 19 Department of Cardiothoracic Surgery, Erasmus University Medical Center, Room Rg-633,
- PO Box 2040, 3000 CA Rotterdam, The Netherlands. 20
- 21 Tel: +31-10-7035413;
- Email: j.j.m.takkenberg@erasmusmc.nl 22
- METC approval: MEC-2012-477 23

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 24 ABSTRACT

#### 25 Background

This study investigated male-female differences in clinical and homograft outcomes in dextro-transposition of the great arteries (d-TGA) patients, with ventricular septal defect (VSD) and pulmonary stenosis/atresia (PS/PA), who underwent right ventricular outflow tract (RVOT) reconstruction with a homograft.

#### 30 Methods

All d-TGA with VSD and PS/PA patients receiving a homograft for RVOT reconstruction at
our center from 1986 to 2021 were included. Time-to-event analyses were used for timerelated clinical outcomes and mixed-effects models to characterize homograft function.

## 34 **Results**

35 Twenty-four patients (16 males) in whom 38 homografts were implanted over time were 36 included. Median age at the first homograft implantation was 2.56 years [IQR: 1.26-11.31] and 2.06 years [IQR: 1.28-8.13] for males and females. Two early death (both males) and 37 38 five late deaths (2 males) were observed. Twenty-two RVOT reinterventions (19/3 in males/females) occurred in follow-up (males/females:345.72/173.35 patient-years). The 10-39 year survival probability was 87.5% (95% CI: 67.3-100) for females and 87.1% (95% CI: 40 71.8-100) for males. Freedom from RVOT reintervention at 10-year was 87.5% (95% CI: 41 42 67.3-100) for females and 64.9% (95% CI: 47.9-88.0) for males. RVOT peak gradient 43 increase rate was associated with body growth rate (7.27 [95% CI: 2.08-12.45], P=0.0133).

## 44 Conclusions

Substantial male-female differences in clinical and homograft outcomes were found in dTGA with VSD and PS/PA patients receiving a homograft for RVOT reconstruction. Male
patients had a higher RVOT reintervention rate and faster progression to homograft stenotic

- 48 failure compared to females. Oversized homografts might benefit children for the strong
- 49 association between rates of homograft stenosis and body growth.
- 50 Keywords: Transposition of the great arteries, male-female differences, homograft, right
- 51 ventricular outflow tract

## 53 Clinical Perspective

- 54 1. What is new?
- Male patients diagnosed with d-TGA, VSD, and PS/PA demonstrated a significantly
   higher rate of RVOT homograft reinterventions and a more rapid progression toward
   homograft stenotic failure when compared with their female counterparts.
- The male-female differences in clinical outcomes and homograft function may be
   attributed, in part, to the faster body growth observed in male children, especially
   given the strong association between rates of homograft stenosis and body growth.
- 61
- 62 2. What are the clinical implications?
- For rapidly growing young children, opting for a suitably oversized homograft might
  serve as a more effective solution in reducing the rate of homograft stenotic failure.
- By exploring the relationship between homograft stenosis rate and individual body
  growth rate for each child, a personalized approach can be adopted during the
  homograft selection process, optimizing the sizing strategy for a better clinical
  outcome.
- 69

# 70 INTRODUCTION

Dextro-transposition of the great arteries(d-TGA) with ventricular septal defect 71 (VSD) and pulmonary stenosis (PS) or pulmonary atresia (PA) is a rare congenital heart 72 73 defect (CHD) that requires early palliative or corrective operations to enable patients' survival<sup>1</sup>. Despite various corrective options available, dysfunction of the right ventricular 74 outflow tract (RVOT) conduit is almost inevitable during a patient's lifetime<sup>2</sup>. If feasible, 75 implantation of a valve substitute with a homograft is the preferred choice to address this 76 issue<sup>3</sup>. As most patients received their first homograft as a RVOT conduit during childhood, a 77 78 period of rapid body growth and development, the homograft function evolution differs from 79 that observed in adults<sup>4</sup>. Additionally, considering the distinct growth patterns between boys 80 and girls<sup>5</sup>, there may be male-female differences in clinical outcomes and homograft function 81 in d-TGA, VSD, PS/PA patients who received homograft as a RVOT conduit during childhood. 82

Despite the importance of studying this patient group, limited research has been done
on these patients, particularly in terms of sex-specific outcomes. Thus, this study aimed to
explore male-female differences in clinical outcomes and homograft function after
homograft RVOT reconstruction in patients diagnosed with d-TGA, VSD, PS/PA.

#### 87 PATIENTS AND METHODS

This is a retrospective single-center study. The medical ethics committee (METC) of the Erasmus University Medical Center reviewed and approved this study (MEC-2012-477). Informed consent was obtained from all participants alive. No consent from deceased patients was necessary according to the medical ethics regulations of our medical center.

# 92 **1. Study population**

All d-TGA patients who underwent RVOT reconstruction with a homograft at
Erasmus University Medical Center from April 1986 to December 2021 were identified.

Patients not surgically corrected, without VSD and PS/PA, or alive but not giving their
consents were excluded. Patients who underwent univentricular repair were also excluded.

#### 97 **2. Data collection**

98 Baseline characteristics, perioperative information, clinical outcomes and echocardiographic parameters during follow-up were extracted by reviewing medical records. 99 Events were defined according to the Akins 2008 guidelines <sup>6</sup>. Early events were defined as 100 all events occurring within the first 30 days after operation. Any events occurring after 30 101 102 days postoperative were defined as late events. Structural valve deterioration (SVD) was 103 defined as stenosis or regurgitation relevant to pulmonary valve without diagnosis of endocarditis. The severities of stenosis and regurgitation were classified in compliance with 104 the ESC/EACTS 2021 guidelines<sup>7</sup>. Stenosis was graded as mild (<36mmHg), moderate (36-105 106 64mmHg), and severe (>64mmHg). Regurgitation was graded as zero/trace, mild, moderate, 107 and severe.

#### 108 **3. Statistical methods**

109 Continuous data are presented as mean  $\pm$  standard deviation (normal distribution) or median with interquartile range (IQR) (non-normal distribution). Categorical data are 110 111 presented as absolute count with percentages. Comparisons among continuous variables were made with the independent samples t-test or Kruskal-Wallis test, as appropriate. Comparisons 112 of categorical data were made with the Chi-square test or Fisher's exact test, as appropriate<sup>8</sup>. 113 114 The Shapiro-Wilk test and visual inspections were used to test the normality. The adverse 115 event rate (AER) for clinical outcomes was calculated as total number of observed events over time (including repeated events) divided by total patient-years of follow-up. Survival 116 117 data are presented as Kaplan-Meier estimates with a standard error or in the form of Kaplan-Meier curves. The log-rank test was used to compare survival outcomes in male and female 118 119 patients. Fine-Gray sub-distribution hazard models were used for competing risk analysis,

with death being the competing event, and the sex-specific cumulative incidence of
homograft reintervention and endocarditis was plotted based on the results<sup>9</sup>.

Two echocardiographic parameters were analyzed to assess homograft function, with 122 123 only sex, time, and their interaction term as covariates to prevent overfitting. The RVOT peak gradient was evaluated using linear mixed-effects models with random intercepts for 124 125 homografts. The degree of regurgitation was dichotomized as < moderate or ≥moderate and analyzed using logistic mixed-effects models with random intercepts for homografts. In 126 127 patients younger than 16 years old, the longitudinal evolution of RVOT peak gradient was 128 correlated to the longitudinal evolution of body surface area (BSA) by multivariate (multiple outcomes) mixed modeling<sup>10</sup>. The correlation between RVOT peak gradient and BSA was 129 130 taken into account via the random effects of the model, in particular a multivariate normal 131 distribution was assumed for the variance-covariance matrix of the random effects. Additionally, random slopes of BSA and RVOT peak gradient were predicted in their 132 respective linear mixed-effects models, and associations between them were explored in 133 134 linear regression model. Sensitivity analysis was conducted by temporarily excluding all measurements of one homograft at a time (leave-one-out sensitivity analysis). The estimates 135 136 and their 95% CIs were visualized respectively for each model parameter. Linear mixedeffects models with the same structure were then constructed, and the results were compared 137 138 with the full model without any exclusion. A P-value less than 0.05 was considered 139 statistically significant, and no correction for multiple testing was applied. Statistical analyses were performed with R statistical program (R Foundation for Statistical Computing, Version 140 4.2.2. https://www.R-project.org/). 141

#### 142 **RESULTS**

#### 143 **1. Baseline characteristics and perioperative information**

A total of 24 patients (16 males, 8 females), in whom 38 homografts (29 in males, 9 in 144 145 females) were used for RVOT reconstructions, were included. Patient baseline characteristics are presented in Table 1. The perioperative information for each homograft implantation 146 147 procedures is provided in Supplementary material Table S1. Two patients died during hospitalizations (early death) for homograft replacement. Both of them were males: one died 148 149 of refractory bleeding and hemorrhagic shock 3 days after operation; one died of septic shock 150 53 days after the operation. No other early endocarditis or reintervention for homograft was observed. 151

## 152 **2.** Clinical outcomes

The median length of follow-up was 28.71 years (IQR: 7.30-31.57; patient-years: 345.72) in male patients and 26.24 years (IQR: 12.22-31.95; patient-years: 173.35) in female patients . The completeness of follow-up was 95.98 %, calculated by the method proposed by Wu et al.<sup>11</sup>. **Figure 1** displays the time slots of key d-TGA-related events in each patient's journey from birth to death or the end of follow-up, separated by sex. These events include d-TGA corrective operation, first RVOT reconstruction with homograft, subsequent RVOT relevant procedures, homograft endocarditis, and mortality or end of follow-up.

160 *2.1 Late mortality* 

In total, five late deaths (2 males/ 3 females) occurred during follow-up. Reasons for three deaths in females were as follows: death while awaiting surgery for severe homograft stenosis, erysipelas-induced septic shock, and severe arrhythmia, respectively. Two male patients were found dead at home without clear explanations. The AERs of late death are presented in **Table 2**. The Kaplan-Meier estimates of overall survival are shown in **Figure 2**.

166 The 5-,10-,15-, and 20-year survival probabilities of male and female patients are presented

167 in **Table 3**.

168 2.2 Homograft reintervention

During follow-up, 10 patients (8 males/2 females) received 22 reinterventions (7 percutaneous, 15 surgical). Of all reinterventions, 17 were pulmonary valve replacement (3 percutaneous, 14 surgical). The AERs of late reinterventions and replacement male and female patients are presented in **Table 2.** Most reinterventions were for stenotic SVD, and two homografts were replaced due to endocarditis. Most surgical replacement procedures were performed in male patients (13/14, 92.9%). Details of all reintervention cases are presented in **Supplementary material Table S2**.

The cumulative incidence of RVOT reintervention with death as a competing event 176 177 was visualized and is presented in Figure 3. Male patients had a significant higher 178 cumulative incidence of RVOT reintervention compared to female patients (Gray's test: P=0.0296). The Kaplan-Meier estimates of freedom from RVOT replacement are shown in 179 180 Supplementary material Figure S1. The 5-,10-,15-, and 20-year probabilities of freedom from RVOT reintervention and replacement in male and female patients are presented in Table 3. 181 Additionally, the Kaplan-Meier estimates of freedom from RVOT percutaneous/surgical 182 reintervention and percutaneous/surgical replacement are shown in Supplementary material 183 184 Figure S2-S5.

185 *2.3 Endocarditis* 

There were 4 homografts with endocarditis (all males), of which two required surgical homograft replacement. The AERs of endocarditis are presented in **Table 2**. The cumulative incidence of homograft endocarditis with death as the competing event was visualized and is presented in **Figure 4**. The 5-,10-,15-, and 20-year probabilities of freedom from endocarditis are presented in **Table 3**.

## 191 **3. Homograft function**

192 The study encompassed 257 echocardiographs conducted on 33 homografts implanted 193 in 20 patients(14 males, 6 females). The total echocardiographic follow-up time was 359.41 194 patient-years, with male patients contributing 264.14 patient-years and female patients 195 contributing 95.27 patient-years. The completeness of echocardiographic follow-up was 83.2 196 %, calculated by the method proposed by Wu *et al.*<sup>11</sup>.Three patients moved abroad after the 197 operations and no further echocardiographic information is available.

198 *3.1 Echocardiographic measurements* 

The evolution of RVOT peak gradient for each included patient was visualized and is
presented respectively for male and female patients in Supplementary material Figure S6-S7.
Different homografts in the same patient were plotted in the same panel using different lines.

202 Results of linear mixed-effects models for RVOT peak gradient are shown in 203 Supplementary material Table S3. Male and female patients exhibited different rates of 204 progression to stenosis, with males progressing at a faster rate (p=0.0272). The results of 205 sensitivity analysis are presented in Supplementary material Figure S8, revealing significant disparities between the results of the five leave-one-homograft-out analyses and those of the 206 207 full model. Results of logistic mixed-effects models for moderate or higher homograft 208 regurgitation are displayed in Supplementary material Table S4, and its sensitivity analysis results are shown in Supplementary material Figure S9. The effect plots of RVOT peak 209 210 gradient and probability of moderate or higher homograft regurgitation are presented in 211 Figure 5.

212 *3.2 Associations between RVOT peak gradient and BSA in patients younger 16 years* 

One hundred eighty-seven BSA measurements were collected from 22 patients younger than 16 years when receiving homografts for RVOT reconstruction. Results of linear mixed-effects models for BSA evolution are presented in Supplementary material Table S5.

216 The results of the two mixed-effects models for longitudinal evolutions of RVOT peak 217 gradient and children's BSA and their correlation matrix of random effects are exhibited in Supplementary material Table S6. The effect plot of BSA increase over time is shown in 218 219 Supplementary material Figure S10. A faster increase of BSA over age was observed in boys 220 compared to girls. The random slope of RVOT peak gradient over patient's time-varying age 221 was positively correlated to the slope of BSA over patient's time-varying age (R = 0.5621). 222 Furthermore, a linear regression between the increase of RVOT peak gradient and BSA over 223 time revealed BSA growth rate was significantly association with RVOT peak gradient 224 acceleration rate (7.27 [95% CI: 2.08-12.45], P = 0.0133). This association suggests the role 225 of somatic growth in homograft stenotic failure. The effect estimate of BSA over time is 226 presented for a 0.1 unite increase for its small scale.

#### 227 **DISCUSSION**

This study focused on male-female differences in clinical outcomes of d-TGA, VSD, 228 229 PS/PA patients who received a homograft implantation for RVOT reconstruction, and the 230 long-term course of homograft (dys)function. It shows that male patients have a higher rate of RVOT reintervention, especially reoperations, compared to female patients. Furthermore, a 231 232 more rapid progression of homograft stenosis was observed in male patients, highlighting the 233 significance of considering sex-specific factors when planning treatment and monitoring 234 patient outcomes. On top of that, a strong association between the increase rates of BSA and 235 RVOT peak gradient was found, underlining the necessity of accounting for the accelerated 236 body growth experienced by young children. In light of this strong association, the use of 237 oversized homografts during RVOT reconstruction might offer benefits for children with d-238 TGA, VSD, PS/PA, especially in younger children and boys, as they grow faster in body 239 size.

Multiple factors may contribute to the observed male-female differences in this study, encompassing both biological (*sex*) factors such as body growth rate and hormonal influences, and socio-cultural (*gender*) aspects like societal norms and roles<sup>12</sup>. In order to comprehensively understand and utilize these differences in a clinically meaningful manner, it is essential to examine both sex and gender aspects within the context of clinical outcomes and homograft function.

#### 246 **1. Homograft reintervention**

Many studies concentrating on outcomes of patients undergoing homograft replacement have found a higher rate of homograft reinterventions in males<sup>13-15</sup>, which is consistent with findings in this study. Several potential reasons may explain the phenomenon, e.g., anatomy and physiology, hormonal level, body size and growth rate, etc<sup>16,17</sup>.

251 Young children are more prone to early homograft degeneration compared to adults, due to prosthesis-patient mismatch developing over time, as a result of somatic growth<sup>4,18</sup>. In 252 253 this study, most of the included patients received their first homograft for RVOT 254 reconstructions before the age of 10, during which their body size rapidly increases over time. Consistent with previous research indicating an accelerated growth rate in young boys 255 compared to girls<sup>5</sup>, our study cohort mirrored the same trend. The divergent growth rates may 256 257 contribute to an increased occurrence of prosthesis-patient mismatch cases in male patients, 258 and consequently, more reinterventions.

Furthermore, the observed male-female differences may be influenced by sex-specific hormones. During puberty, testosterone levels increase substantially in male adolescents, while estrogen levels rise dramatically in female adolescents<sup>19,20</sup>. Interestingly, these two sex steroid hormones have been found to be correlated with serum calcium levels<sup>21</sup>. Specifically, estrogen has been linked to reducing serum calcium, whereas testosterone has been

associated with its elevation<sup>21</sup>. The potential impact of their regulatory roles on serum
calcium could potentially impact the risk of homograft calcifications and degeneration.

On top of the aforementioned biological factors, gender may also contribute to the higher rate of reinterventions in male patients. Children's gender might influence their parents' care-seeking behavior for them, especially in low- and middle- income countries<sup>22</sup>. This may not directly apply to the current study, given that the Netherlands is a high-income country. Further information regarding patients and their families social-economic status would help validate whether children's gender interacts with family income levels, potentially affecting parents' healthcare-seeking decisions for their children.

Symptoms are an important part of criteria for heart valve reinterventions<sup>7</sup>. As indicated in some clinical research, male and female patients may differ in clinical symptoms, with female patients more likely to experience atypical symptoms<sup>23-25</sup>. The atypical symptoms might deter doctors from performing potentially necessary reinterventions in female patients, thereby causing a lower rate of reinterventions in female patients compared to male patients.

# 279 2. Homograft stenosis

In this study, out of the 22 reintervention cases, 18 were attributed to homograft 280 stenotic failure. The RVOT peak gradient serves as a common echocardiographic parameter 281 282 for assessing valve stenosis. Its evolution reflects the progression of stenosis. As depicted in 283 Figure 5, male patients demonstrated a faster increase rate of RVOT peak gradient, implying a more rapid development of stenosis compared to their female counterparts. As previously 284 285 discussed, prosthesis-patient mismatch could be a contributing factor to reinterventions for 286 stenosis in young children. The observed faster stenotic development in male patients might be attributed to a higher incidence of prosthesis-patient mismatch in this group, as boys tend 287 to grow faster than girls<sup>5</sup>. Our investigation of the relationship between the evolutions of 288

BSA and RVOT peak gradient revealed a strong correlation, suggesting that faster BSA increase is correlated with a more rapid progression of RVOT peak gradient. Considering this strong correlation, accounting for children's future body growth may become essential for clinicians, necessitating the consideration of different homograft sizing for boys and girls to provide more patient-specific clinical management.

294 Echocardiograph is commonly used to measure homograft function. Usually the time 295 interval between two consecutive measurements depends on the decision made by both 296 doctors and patients. As mentioned previously, female patients are inclined to exhibit more atypical symptoms or even remain asymptomatics<sup>23-25</sup>. On one hand, doctors may feel 297 298 reluctant to prescribe appropriate treatment/examinations when facing patients with atypical 299 symptoms. On the other hand, patients with non- or atypical-symptoms might be more likely 300 to decline necessary homograft function evaluations, potentially leading to distortions of the 301 observed evolutions of RVOT peak gradient. Consequently, (symptomatic) male patients received more echocardiographic examinations, capturing higher RVOT peak gradient 302 303 values, which might contribute to the observed accelerated progression of homograft stenosis 304 in male patients compared to their female counterparts.

## 305 **3. Limitations**

306 First and foremost, a notable limitation of this study is the very small sample size, 307 which may have decreased the statistical power to detect the significant differences of the 308 observation of many important clinical events during the follow-up period. Additionally, the application of complex modeling methods, such as (multivariate) mixed-effects models, in 309 310 such a small dataset may lead to overfitted estimates, further warranting cautious 311 extrapolation of results to other patients. Additionally, only linear relations between length of follow-up time and repeated measurements (RVOT peak gradient,  $\geq$  moderate or higher 312 313 pulmonary regurgitation) were taken into account to avoid potential overfitting issue.

However, nonlinear relations between time and longitudinal outcomes are common in clinical research<sup>26</sup>. It is necessary to account for nonlinearity when larger sample size is available. Furthermore, reinterventions are recurrent events and should be analyzed using recurrent event survival analysis. However, it is not feasible due to the small sample size, and only the first reintervention was considered for survival analysis in this study. It might affect the estimates of reintervention hazard. Lastly, this is a retrospective study, and its inherent limitations also apply for this study<sup>27</sup>.

#### 321 Conclusion

322 In our single-center experience, there are substantial male-female differences in terms of clinical outcomes and homograft function over time in d-TGA, VSD, PS or PA patients 323 who receive homografts for RVOT reconstruction during or after corrective operations. 324 325 Given the association between the rate of body growth, notably faster in boys, and the progression of homograft stenosis, somatic growth might contribute to the higher 326 327 reintervention rate in males. To address this, we recommend employing oversized homografts 328 that account for future increases of body size in young patients when their body size can be measured accurately and the (properly) over-sized homograft is available. Furthermore, the 329 330 oversizing criteria should be established sex-specifically in light of different body growth rates in young female and male patients. 331

## 332 ACKNOWLEDGMENTS

333 Not applicable

## 334 FUNDING STATEMENT

335 None

## 336 CONFLICT OF INTEREST STATEMENT

337 Nothing to declare.

## 338 AUTHOR CONTRIBUTION STATEMENT

XW: Conceptualization; Data collection and validation; Statistical analyses; Writing and
editing. IMB: Conceptualization; Data collection and validation; Statistical analyses; Writing
and editing. KMV: Methodological supervision; Results validation; Manuscript review and
editing. PCW: Data validation; Manuscript review and editing. CCEMV: Data collection;
Manuscript review and editing. AJJCB: Results validation; Manuscript review and
editing. WAH: Results validation; Manuscript review and editing. JJMT: Conceptualization;
Supervision; Data and results validation; Manuscript review and editing.

Characteristic		Total Male patients		Female patients	<b>P-</b>	
		n = 24	n = 16	n = 8	value	
Age (correction), years		2.21 (1.09, 5.44)	2.31 (1.06, 4.66)	1.80 (1.09, 7.07)	0.928	
Age, years § 1 <sup>st</sup> homograft		2.34 (1.26, 9.17)	2.56 (1.26, 11.31)	2.06 (1.28, 8.13)	0.742	
	2 <sup>nd</sup> homograft	12.75 (8.14, 17.88)	15.11 (7.72, 19.11)	*		
<b>Corrective pr</b>	ocedure with	18 (75.0)	13 (81.3)	5 (62.5)	0.617	
homograft, n	(%)					
Times of hom	ograft implantations,	, n (%) §			0.311	
-	First	24 (100.0)	16 (100.0)	8 (100.0)		
-	Second	9 (37.5)	8 (50.0)	1 (12.5)		
-	Third	3 (12.5)	3 (18.8)	0 (0.0)		
-	Fourth	2 (8.3)	2 (12.5)	0 (0.0)		
Homograft ty	pe, pulmonary, n (%	) §		0.453		
- F	First homograft	11 (45.8)	6 (37.5)	4 (50.0)		
- Se	cond homograft	7 (77.8)	6 (75.0)	1 (100.0)		
- T	hird homograft	1 (33.3)	1 (33.3)	0 (0.0)		
- Fe	ourth homograft	2 (100.0)	2 (100.0)	0 (0.0)		
Homograft di	ameter, mm*	$18.67 \pm 3.52$	$18.69 \pm 2.91$	$18.63 \pm 4.75$	0.974	
BSA, m <sup>2</sup> †		0.51 (0.41, 1.05)	0.52 (0.42, 1.26)	0.49 (0.39, 0.86)	0.691	
BID, $mm/m^2$ .	ŧ	34.12 (20.24,	34.12 (16.63,	35.25 (28.22,	0.927	
		41.18)	41.18)	40.40)		
Associated an	omalies, n (%)				0.385	
- PA		2 (8.3)	2 (12.5)	0 (0.0)		
- ASD		8 (33.3)	3 (18.8)	5 (62.5)		
- DORV		6 (25.0)	2 (12.5)	4 (50.0)		
- PDA		1 (4.2)	0 (0.0)	1 (12.5)		
- Aorta a	nomalies‡	3 (12.5)	1 (6.3)	2 (25.0)		
- DCRV		1 (4.2)	1 (6.3)	0 (0.0)		
- Pulmor	nary artery anomalies	2 (8.3)	2 (12.5)	0 (0.0)		
- Corona	ry artery anomalies	1 (4.2)	1 (6.3)	0 (0.0)		
- Pulmor	nary vein anomalies	1 (4.2)	1 (6.3)	0 (0.0)		
- Нурор	lastic RV	1 (4.2)	0 (0.0)	1 (12.5)		
<b>Corrective Op</b>	peration, n (%)				1.000	
- Rastell	i procedure	20 (83.3)	13 (81.3)	7 (87.5)		
- REV p	rocedure	2 (8.3)	2 (12.5)	0 (0.0)		
- ASO procedure		2 (8.3)	1 (6.2)	1 (12.5)		
Palliative procedures, n (%)						
- No pall	liative procedure	7 (29.2)	6 (37.5)	1 (12.5)		
- BT or l	Modified BT shunt	10 (41.7)	6 (37.5)	4 (50.0)		
- Waters	ton shunt	3 (12.5)	1 (6.3)	2 (25.0)		
- Potts sl	nunt	1 (4.2)	1 (6.3)	0 (0.0)		
- Rashki	nd procedure	6 (25.0)	3 (18.8)	3 (37.5)		
- Central shunt	l aorto-pulmonary	2 (8.3)	1 (6.3)	1 (12.5)		

240	<b>T</b> . <b>L</b> L 1 <b>D</b> 1'	1			VOD	1		
346	Table I: Baseline	characteristics	of d-IGA	patients with	VSD,	pulmonary	y stenosis	or atresia

347 Data are presented as median (IQR) or mean ± SD. BSA: body surface area; BID: BSA indexed diameter,

348 calculated using homograft diameter divided by BSA; PA: pulmonary atresia; ASD: atrial septal defect; DORV:

349 double outlet right ventricle; PDA: patent ductus arteriosus; DCRV: double-chambered right ventricle; RV:

- 350 Right ventricle; REV procedure: réparation à l'ètage ventriculaire; ASO: arterial switch operation; BT Shunt: 351 Blalock-Taussig shunt; IQR: interquartile range; SD: standard deviation.
- 352 §: the 1st /2nd /3rd homograft here refer to the homograft that patients received during their first/second/third
- 353 RVOT reconstruction with homograft procedures. The sum of all these numbers in each column is the total
- 354 number of RVOT homograft, which is larger than the number of patients since one patient can receive multiple

355 homografts sequentially.

- 356 \*: Values here are only about the diameter of the first homograft used for RVOT reconstruction.
- 357 †: BSA and BID are the values measured prior to the operation of the first RVOT reconstruction with a 358 homograft.
- 359 : Aorta anomalies: Aortic Arch Coarctation/hypoplasia/interrupted aortic arch, Overriding Aorta.
- 360 \*: Only one second homograft in females. Quantiles cannot be computed.
- 361

		Males (	n = 16)	Females	( <b>n</b> = <b>8</b> )	P-values
		Ν	AER (95%CI)	Ν	AER (95%CI)	
FUP, years		28.71 (7.30, 31.57)		26.24 (12.22, 31.95)		
Patient-years		345.72		173.35		
Late	All-cause	2	0.58 (0.07-2.09)	3	1.73 (0.36-5.06)	0.207
mortality	-Cardiac	2	0.58 (0.07-2.09)	2	1.15 (0.14-4.17)	0.481
	-Valve-related	2	0.58 (0.07-2.09)	1	0.58 (0.01-3.21)	0.998
Late reinte	Late reinterventions		5.50 (3.31-8.58)	3	1.73 (0.36-5.06)	0.049
- Per	- Percutaneous		1.45 (0.47-3.38)	2	1.15 (0.14-4.17)	0.787
- Surgical		14	4.05 (2.21-6.79)	1	0.58 (0.01-3.21)	0.028
Replacement		16	4.63 (2.65-7.52)	1	0.58 (0.01-3.21)	0.016
- Percutaneous		3	0.87 (0.18-2.54)	0	0 (0-2.13)	0.220
- Surgical		13	3.76 (2.00-6.43)	1	0.58 (0.01-3.21)	0.037
Endocarditis		4	1.16 (0.32-2.97)	0	0 (0-2.13)	0.157
PPMI/ICD		2	0.58 (0.07-2.09)	1	0.58 (0.01-3.21)	0.997

362	Table 2: Number of events and adverse event rates in male and female patients
363	

N: number of events; AER: adverse event rate, patient-years divided by number of events; CI: confidence interval; FUP: length of follow-up; PPMI: permeant pacemaker implantation; ICD: Implantable cardioverter

364 365 366 defibrillator.

506 replacement and endocarditis								
Event	Sex	5 years	10 years	15 years	20 years			
Patients Survival*, %	Female	87.5 (67.3-100)	87.5 (67.3-100)	72.9 (46.8-100)	72.9 (46.8-100)			
	Male	87.1 (71.8-100)	87.1 (71.8-100)	87.1 (71.8-100)	87.1 (71.8-100)			
Freedom from	Female	100 (100-100)	87.5 (67.3-100)	87.5 (67.3-100)	66.5 (35.2-100)			
reintervention <sup>†</sup> , %	Male	83.4 (69.8-99.7)	64.9 (47.9-88.0)	38.1 (21.7-66.9)	23.8 (9.9-57.1)			
- Percutaneous	Female	100 (100-100)	100 (100-100)	100 (100-100)	75.0 (42.6-100)			
	Male	100 (100-100)	94.7 (85.2-100)	74.6 (52.6-100)	74.6 (52.6-100)			
- Surgical	Female	100 (100-100)	87.5 (67.3-100)	87.5 (67.3-100)	87.5 (67.3-100)			
	Male	83.4 (69.8-100)	69.5 (52.9-91.3)	53.8 (36.1-80.2)	27.7(11.5-66.3)			
Freedom from	Female	100 (100-100)	87.5 (67.3-100)	87.5 (67.3-100)	87.5 (67.3-100)			
replacement <sup>†</sup> , %	Male	87.5 (75.1-100)	69.0 (52.3-91.1)	47.5 (29.9-75.5)	29.7 (13.1-67.0)			
- Percutaneous	Female	100 (100-100)	100 (100-100)	100 (100-100)	100 (100-100)			
	Male	100 (100-100)	94.7 (85.2-100)	85.3 (67.6-100)	85.3 (67.6-100)			
- Surgical	Female	100 (100-100)	87.5 (67.3-100)	87.5 (67.3-100)	87.5 (67.3-100)			
	Male	87.5 (75.1-100)	73.6 (57.5-94.3)	52.3 (34.4-79.6)	26.9 (11.1-65.1)			
Freedom from	Female	100 (100-100)	100 (100-100)	100 (100-100)	100 (100-100)			
endocarditis†, %	Male	96.0 (88.6-100)	85.3(71.0-100)	85.3(71.0-100)	71.1 (47.5-100)			

367 Table 3: Probabilities of cumulative survival, and freedom from homograft reintervention, replacement and endocarditis 368

rditist, %Male96.0 (88.6-100)85.3(71.0-100)85.3(71.0-100)71.1 (47.5-1\*: Survival probability was calculated on patient-level. †: Probabilities of freedom from reintervention, 369 370 replacement, and endocarditis were calculated on homograft-level. All probabilities are presented in the format 371 of absolute percent (95% confidence interval).



Figure 1: Event timelines of patients with d-TGA/VSD and PS or PA. Each point on the x-axis represents one patient. Each horizontal line stands for the time span of on patient from his or her birth to death or the end of the follow-up. Diamonds of different colors represent different events. All events were arranged chronologically, with the corresponding values on y-axis indicating the age of event occurrence. Patient "P5" died 3 days after the last homograft PVR operation. "PVR": pulmonary valve replacement; "Homograft PVR" is a synonym for RVOT reconstruction with homograft. 



390

Figure 2: Kaplan-Meier survival estimates in male and female patients. The number-at-risk is 391 the number of patients at risk at different time points(not the number of homograft). Log-rank

392 test was used here. 393



Figure 3: Cumulative incidence of receiving RVOT reinterventions in homografts implanted 394

in male and female patients. 395



Figure 4: Cumulative incidence of homograft endocarditis in male and female patients.





Figure 5: Effect plots of A: RVOT peak gradient change over time in male and female 398 399 patients; B: probabilities of having moderate or higher pulmonary regurgitation over time in 400 male and female patients.

## 402 **REFERENCES**

Carole AW. Transposition of the Great Arteries. Circulation. 2006;114(24):2699-403 1. 404 2709. doi:doi:10.1161/CIRCULATIONAHA.105.592352 Hornung TS, Derrick GP, Deanfield JE, Redington AN. Transposition complexes in 405 2. the adult: a changing perspective. Cardiology Clinics. 2002/08/01/2002;20(3):405-420. 406 407 doi:https://doi.org/10.1016/S0733-8651(02)00012-7 408 Romeo JLR, Mokhles MM, van de Woestijne P, et al. Long-term clinical outcome 3. 409 and echocardiographic function of homografts in the right ventricular outflow tract<sup>+</sup>. Eur J 410 Cardiothorac Surg. Mar 1 2019;55(3):518-526. Henaine R, Roubertie F, Vergnat M, Ninet J. Valve replacement in children: a 411 4. 412 challenge for a whole life. Arch Cardiovasc Dis. Oct 2012;105(10):517-28. 413 5. Kozieł S. Relationships among tempo of maturation, midparent height, and growth in 414 height of adolescent boys and girls. Am J Hum Biol. Jan-Feb 2001;13(1):15-22. 415 Akins CW, Miller DC, Turina MI, et al. Guidelines for reporting mortality and 6. 416 morbidity after cardiac valve interventions. Ann Thorac Surg. Apr 2008;85(4):1490-5. 417 7. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the 418 management of valvular heart disease. Eur Heart J. Feb 12 2022;43(7):561-632. 419 Kim HY. Statistical notes for clinical researchers: Chi-squared test and Fisher's exact 8. 420 test. Restor Dent Endod. May 2017;42(2):152-155. 421 Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model 9. 422 analyses for competing risk data. Stat Med. Nov 30 2017:36(27):4391-4400. 423 Rizopoulos D. The R Package JMbayes for Fitting Joint Models for Longitudinal and 10. 424 Time-to-Event Data Using MCMC. Journal of Statistical Software. 2016;72(7):1 - 46. 425 doi:10.18637/jss.v072.i07 426 11. Wu Y, Takkenberg JJ, Grunkemeier GL. Measuring follow-up completeness. Ann 427 Thorac Surg. Apr 2008;85(4):1155-7. 428 12. Bewley S, McCartney M, Meads C, Rogers A. Sex, gender, and medical data. Bmj. 429 2021;372:n735. doi:10.1136/bmj.n735 430 13. Oeser C, Uyanik-Uenal K, Kocher A, Laufer G, Andreas M. Long-term performance 431 of pulmonary homografts after the Ross procedure: experience up to 25 years. Eur J Cardiothorac Surg. May 1 2019;55(5):876-884. 432 433 Caldarone CA, McCrindle BW, Van Arsdell GS, et al. Independent factors associated 14. 434 with longevity of prosthetic pulmonary valves and valved conduits. J Thorac Cardiovasc 435 Surg. Dec 2000;120(6):1022-30; discussion 1031. 436 15. Zubairi R, Malik S, Jaquiss RDB, Imamura M, Gossett J, Morrow WR. Risk Factors 437 for Prosthesis Failure in Pulmonary Valve Replacement. The Annals of Thoracic Surgery. 438 2011/02/01/ 2011;91(2):561-565. doi:https://doi.org/10.1016/j.athoracsur.2010.07.111 439 16. Schoen FJ, Levy RJ. Calcification of tissue heart valve substitutes: progress toward 440 understanding and prevention. Ann Thorac Surg. Mar 2005;79(3):1072-80. Jiao L, Machuki JO, Wu Q, et al. Estrogen and calcium handling proteins: new 441 17. 442 discoveries and mechanisms in cardiovascular diseases. Am J Physiol Heart Circ Physiol. 443 Apr 1 2020;318(4):H820-H829. 444 David TE. Aortic Valve Replacement in Children and Young Adults\*. Journal of the 18. 445 American College of Cardiology. 2016/06/21/ 2016;67(24):2871-2873. 446 doi:https://doi.org/10.1016/j.jacc.2016.04.023 447 19. Courant Fdr, Aksglaede L, Antignac J-P, et al. Assessment of Circulating Sex Steroid 448 Levels in Prepubertal and Pubertal Boys and Girls by a Novel Ultrasensitive Gas 449 Chromatography-Tandem Mass Spectrometry Method. The Journal of Clinical 450 Endocrinology & Metabolism. 2010;95(1):82-92. doi:10.1210/jc.2009-1140

- 451 20. Khan L. Puberty: Onset and Progression. Pediatr Ann. Apr 1 2019;48(4):e141-e145.
- 452 21. Van Hemelrijck M, Michaelsson K, Nelson WG, et al. Association of serum calcium 453 with serum sex steroid hormones in men in NHANES III. Aging Male. Dec 2013;16(4):151-454 8.
- 455 22. Sharif AI, Amy M, Sufang G, Alyssa S, Sheeba H, Paul R. Gender-related differences in care-seeking behaviour for newborns: a systematic review of the evidence in South Asia. 456
- 457 BMJ Global Health. 2019;4(3):e001309. doi:10.1136/bmjgh-2018-001309
- 458 Meischke H, Yasui Y, Kuniyuki A, Bowen DJ, Andersen R, Urban N. How women 23. 459 label and respond to symptoms of acute myocardial infarction: responses to hypothetical 460 symptom scenarios. Heart Lung. Jul-Aug 1999;28(4):261-9.
- Dempsey SJ, Dracup K, Moser DK. Women's decision to seek care for symptoms of 461 24. acute myocardial infarction. Heart Lung. Nov-Dec 1995;24(6):444-56. 462
- 463 25. Davis LL, Mishel M, Moser DK, Esposito N, Lynn MR, Schwartz TA. Thoughts and 464 behaviors of women with symptoms of acute coronary syndrome. Heart Lung. Nov-Dec 465 2013;42(6):428-35.
- Wang X, Andrinopoulou ER, Veen KM, Bogers A, Takkenberg JJM. Statistical 466 26.
- 467 primer: an introduction to the application of linear mixed-effects models in cardiothoracic
- surgery outcomes research-a case study using homograft pulmonary valve replacement data. 468
- *Eur J Cardiothorac Surg.* Sep 2 2022;62(4) 469
- 470 27. Bellomo R, Warrillow SJ, Reade MC. Why we should be wary of single-center trials.
- 471 Crit Care Med. Dec 2009;37(12):3114-9.
- 472